Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure

Mozaffarian, 2015, Heart disease and stroke statistics—2015 update: a report from the American Heart Association, Circulation, 131, e29, 10.1161/CIR.0000000000000152

O'Connell, 2000, The economic burden of heart failure, Clin Cardiol, 23, III-6, 10.1002/clc.4960231503

Perna, 2004, Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification, Circulation, 110, 2376, 10.1161/01.CIR.0000145158.33801.F3

van Veldhuisen, 2013, B-Type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction, J Am Coll Cardiol, 61, 1498, 10.1016/j.jacc.2012.12.044

Ky, 2011, High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure, Circ Heart Fail, 4, 180, 10.1161/CIRCHEARTFAILURE.110.958223

Ochieng, 2004, Extracellular functions of galectin-3, Glycoconj J, 19, 527, 10.1023/B:GLYC.0000014082.99675.2f

Dumic, 2006, Galectin-3: an open-ended story, Biochim Biophys Acta, 1760, 616, 10.1016/j.bbagen.2005.12.020

Henderson, 2006, Galectin-3 regulates myofibroblast activation and hepatic fibrosis, Proc Natl Acad Sci U S A, 103, 5060, 10.1073/pnas.0511167103

Liu, 2009, N-Acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin, Am J Physiol Heart Circ Physiol, 296, H404, 10.1152/ajpheart.00747.2008

de Boer, 2010, Galectin-3 in cardiac remodeling and heart failure, Curr Heart Fail Rep, 7, 1, 10.1007/s11897-010-0004-x

Sharma, 2004, Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction, Circulation, 110, 3121, 10.1161/01.CIR.0000147181.65298.4D

Coburn, 2014, Comprehensive review of the prognostic value of galectin-3 in heart failure, Cardiol Rev, 22, 171, 10.1097/CRD.0000000000000013

Tang, 2011, Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival, Am J Cardiol, 108, 385, 10.1016/j.amjcard.2011.03.056

Ueland, 2011, Galectin-3 in heart failure: high levels are associated with all-cause mortality, Int J Cardiol, 150, 361, 10.1016/j.ijcard.2011.05.081

Lopez-Andrès, 2012, Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial, Eur J Heart Fail, 14, 74, 10.1093/eurjhf/hfr151

Lok, 2010, Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the Deal-HF study, Clin Res Cardiol, 99, 323, 10.1007/s00392-010-0125-y

Felker, 2012, Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study, Circ Heart Fail, 5, 72, 10.1161/CIRCHEARTFAILURE.111.963637

Carrasco-Sánchez, 2013, Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction, Int J Cardiol, 169, 177, 10.1016/j.ijcard.2013.08.081

Ahmad, 2014, Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure, JACC Heart Fail, 2, 260, 10.1016/j.jchf.2013.12.004

Bayes-Genis, 2014, Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3, J Am Coll Cardiol, 63, 158, 10.1016/j.jacc.2013.07.087

de Boer, 2011, Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction, Ann Med, 43, 60, 10.3109/07853890.2010.538080

Basuray, 2014, Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes, Circulation, 129, 2380, 10.1161/CIRCULATIONAHA.113.006855

Gaze, 2014, Analytical evaluation of the automated galectin-3 assay on the Abbott Architect immunoassay instruments, Clin Chem Lab Med, 52, 919, 10.1515/cclm-2013-0942

Ky, 2012, Multiple biomarkers for risk prediction in chronic heart failure, Circ Heart Fail, 5, 183, 10.1161/CIRCHEARTFAILURE.111.965020

Heagerty, 2000, Time-dependent ROC curves for censored survival data and a diagnostic marker, Biometrics, 56, 337, 10.1111/j.0006-341X.2000.00337.x

Ho, 2012, Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community, J Am Coll Cardiol, 60, 1249, 10.1016/j.jacc.2012.04.053

Edelmann, 2015, Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial, Eur J Heart Fail, 17, 214, 10.1002/ejhf.203

Mohammed, 2014, Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction, JACC Heart Fail, 2, 113, 10.1016/j.jchf.2013.11.004

Anand, 2003, Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT), Circulation, 107, 1278, 10.1161/01.CIR.0000054164.99881.00

Miller, 2009, Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure, J Am Coll Cardiol, 54, 1715, 10.1016/j.jacc.2009.07.025

Psaty, 2015, Letter by Psaty et al regarding article, “Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes”, Circulation, 131, e343, 10.1161/CIRCULATIONAHA.114.012243

Basuray, 2015, Response to letter regarding article, “Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes, Circulation, 131, e344, 10.1161/CIRCULATIONAHA.114.012888